ALVESCO Drug Patent Profile

When do Alvesco patents expire, and when can generic versions of Alvesco launch?

Alvesco is a drug marketed by Covis and is included in one NDA. There is one patent protecting this drug.

This drug has fourteen patent family members in twelve countries.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ciclesonide profile page.

DrugPatentWatch^® Generic Entry Outlook for Alvesco

Alvesco was eligible for patent challenges on October 20, 2010.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 1, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ALVESCO

International Patents:	14
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	64
Clinical Trials:	11
Drug Prices:	Drug price information for ALVESCO
What excipients (inactive ingredients) are in ALVESCO?	ALVESCO excipients list
DailyMed Link:	ALVESCO at DailyMed

See drug prices for ALVESCO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ALVESCO

Constraining patent/regulatory exclusivity:

8,371,292

NDA:

021658

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ALVESCO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Pittsburgh	PHASE1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	PHASE1
Children's Mercy Hospital Kansas City	PHASE1

See all ALVESCO clinical trials

US Patents and Regulatory Information for ALVESCO

ALVESCO is protected by one US patents.

This potential generic entry date is based on patent 8,371,292.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-002	Jan 10, 2008		RX	Yes	Yes	8,371,292
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008		RX	Yes	Yes	8,371,292

Expired US Patents for ALVESCO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	6,036,942
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	5,683,677
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-002	Jan 10, 2008	5,482,934
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	5,482,934
Covis	ALVESCO	ciclesonide	AEROSOL, METERED;INHALATION	021658-003	Jan 10, 2008	5,695,743

EU/EMA Drug Approvals for ALVESCO

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim Vetmedica GmbH	Aservo EquiHaler	ciclesonide	EMEA/V/C/004991For the alleviation of clinical signs of severe equine asthma (formerly known as Recurrent Airway Obstruction – (RAO), Summer Pasture Associated Recurrent Airway Obstruction – (SPA-RAO)).	Authorised	no	no	no	2020-01-28

International Patents for ALVESCO

See the table below for patents covering ALVESCO around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	983058
Greece	1001529	Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. (PROCESS FOR THE OBTAINMENT OF A NEW PREGNA-1,4-DIENE-3,20-DIONE -16-17-ACETAL-21 ESTERS)
European Patent Office	0995434
Denmark	0673857
European Patent Office	0372777	MEDICINAL AEROSOL FORMULATIONS

Supplementary Protection Certificates for ALVESCO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0983058	CA 2005 00036	Denmark
0983058	SPC022/2005	Ireland		SPC022/2005, 20060612, EXPIRES: 20190415
0983058	PA2005006	Lithuania		PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321
0983058	PA2005006,C0983058	Lithuania		PRODUCT NAME: CICLESONIDUM (11BETA,16ALFA)-16,17-(((R)-CIKLOHEKSILMETILEN)BIS(OKSI))-11-HIDROKSI-21-(2-METIL-1OKSOPROPOKSI)PREGNA-1,4-DIEN-3,20-DIONAS; REGISTRATION NO/DATE: LT/1/05/0181/001, LT/1/05/0181/002, LT/1/05/0181/003 20050321

ALVESCO: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

ALVESCO (ciale) is a dry powder inhaler (DPI) formulation of ciclesonide, a corticosteroid used for the maintenance treatment of asthma. Its market performance is driven by the global burden of asthma, competitive landscape, patent expiry, and pricing strategies.

What is ALVESCO's Core Mechanism and Therapeutic Use?

ALVESCO is a prodrug that is hydrolyzed in the airways to its active metabolite, desisobutoxycarbonyl ciclesonide. This metabolite exhibits potent anti-inflammatory activity, suppressing the release of inflammatory mediators in the airways, which is crucial for managing asthma symptoms. The drug is indicated for the long-term control of asthma in patients aged 12 years and older. Its DPI formulation offers advantages in terms of dose delivery and patient adherence compared to some metered-dose inhalers.

What is the Current Market Size and Projected Growth for ALVESCO?

The global asthma inhalers market, which ALVESCO occupies, is substantial and projected for continued growth. In 2023, the global asthma inhalers market was valued at approximately $20 billion. This market is expected to grow at a compound annual growth rate (CAGR) of 5.5% through 2030, reaching an estimated $29.5 billion. ALVESCO's specific market share is influenced by its therapeutic positioning and competitive pressures. While precise ALVESCO-only revenue figures are not publicly disclosed by all manufacturers, the broader inhaled corticosteroid (ICS) market segment, where ALVESCO competes, is a significant driver of this growth.

Key market drivers include:

• Increasing prevalence of asthma: Environmental factors, urbanization, and changing lifestyles contribute to a rise in asthma diagnoses globally.
• Growing awareness of respiratory diseases: Public health campaigns and improved diagnostic tools increase early detection and treatment.
• Advancements in inhaler technology: Development of more efficient and user-friendly devices enhances patient compliance and therapeutic outcomes.
• Demand for long-term control medications: Patients and healthcare providers seek effective treatments for sustained symptom management and prevention of exacerbations.

Who are ALVESCO's Primary Competitors and What is Their Market Positioning?

ALVESCO competes within the established and highly competitive inhaled corticosteroid (ICS) market. Its primary competitors include other ciclesonide formulations and ICSs from different drug classes.

Key competitors and their positioning:

• Other Ciclesonide Formulations: Manufacturers producing generic or branded versions of ciclesonide DPIs or other delivery systems. These often compete on price and accessibility.
• Fluticasone Propionate (e.g., Flovent, Advair): A widely prescribed ICS, often available in multiple formulations and device types. Advair also combines fluticasone with a long-acting beta-agonist (LABA).
• Budesonide (e.g., Pulmicort): Another commonly used ICS, available in both DPI and nebulized solutions.
• Mometasone Furoate (e.g., Asmanex): Available as a DPI, often positioned as a convenient once-daily option.
• Combination Therapies (ICS/LABA): Drugs like Advair, Symbicort, and Dulera combine an ICS with a LABA for more comprehensive asthma control, often capturing a larger share of the market for moderate-to-severe asthma.

ALVESCO's market positioning relies on its efficacy in asthma control, favorable safety profile, and the convenience of its DPI device. Its differentiation often hinges on clinical trial data demonstrating equivalent or superior outcomes compared to other ICSs in specific patient populations.

What is ALVESCO's Patent Landscape and When Does it Face Generic Competition?

The patent landscape for ALVESCO is critical for its financial trajectory. The primary composition of matter patent for ciclesonide expired in many key markets, opening the door for generic entry.

• US Patent Expiry: The key patents protecting ciclesonide expired in the United States around 2017-2018. This allowed for the introduction of generic ciclesonide products.
• European Patent Expiry: Similar patent expiries occurred in European countries, with many core patents expiring in the early to mid-2010s.
• Formulation and Device Patents: While composition of matter patents are crucial, secondary patents related to specific formulations, manufacturing processes, or the DPI device itself can extend market exclusivity for a branded product to some extent. However, these are generally less robust than composition patents.
• Impact of Generic Entry: The expiration of primary patents has led to significant price erosion for branded ALVESCO as generic alternatives enter the market. This is a standard dynamic in the pharmaceutical industry, where branded drugs experience revenue decline post-patent expiry due to lower-priced generic competition.

The introduction of generic ciclesonide has a direct impact on ALVESCO’s revenue. For instance, after the launch of generic Advair in the US in 2019, the branded product experienced a rapid decline in sales. While ALVESCO is a single-agent ICS, the principle of price erosion due to generic competition is highly relevant.

What is ALVESCO's Financial Performance and Revenue Trends?

Detailed, consistent, and publicly available financial performance data specifically for ALVESCO branded sales is challenging to isolate. This is because pharmaceutical companies often report revenue by therapeutic area or a portfolio of related products, rather than individual drug brands, especially after generic entry. However, general trends for ICSs and the impact of generic competition provide strong indicators.

• Peak Sales Period: Branded ALVESCO would have experienced its highest revenue generation during the period when its primary patents were in force and before significant generic competition emerged. This period would typically be in the late 2000s to the early to mid-2010s.
• Post-Patent Expiry Decline: Following patent expiries in major markets (e.g., 2017-2018 in the US), ALVESCO's revenue would have experienced a substantial decline due to the introduction of generic ciclesonide. Generic products typically capture a significant portion of market volume rapidly due to their lower cost.
• Market Share Erosion: The market share of branded ALVESCO has been eroded by generic ciclesonide. This leads to a decrease in the average selling price (ASP) and overall revenue for the branded product.
• Sales Data Indicators: While not exclusive to ALVESCO, the broader ICS market provides context. For example, GSK’s Flovent (fluticasone propionate), a direct competitor, saw its sales decline from over $1 billion annually before generic entry to a fraction of that after. Nycomed (later Takeda) was the initial developer of ALVESCO (ciclesonide) in Europe. Nycomed was acquired by Takeda in 2011. For a period, Covis Pharma held the US rights. Manufacturers reporting specific ALVESCO sales figures are limited. However, analyses of the ciclesonide market indicate a significant shift towards generics.

Estimates suggest that branded ALVESCO sales have likely fallen by over 70-80% from their peak in major markets due to generic penetration. Remaining sales are driven by physicians and patients who continue to prescribe or use the branded product, often due to formulary agreements, physician preference, or patient familiarity.

What are the Regulatory Considerations and Reimbursement Policies Affecting ALVESCO?

Regulatory and reimbursement policies significantly influence ALVESCO's market access and pricing.

• FDA and EMA Approvals: ALVESCO has received approvals from major regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals signify its safety and efficacy for its intended use.
• Generic Drug Pathways: Regulatory bodies have established pathways for the approval of generic versions of ciclesonide. Generic manufacturers must demonstrate bioequivalence to the branded product.
• Pricing and Reimbursement:
  • Payer Influence: Insurance companies and government health programs (e.g., Medicare, Medicaid in the US; national health services in Europe) exert significant influence on drug pricing and prescribing.
  • Formulary Placement: Inclusion on drug formularies is crucial for market access. Health plans often prefer generics due to lower cost, placing branded ALVESCO at a disadvantage for preferred status.
  • Step-Therapy Requirements: Some payers may implement step-therapy protocols, requiring patients to first try a lower-cost generic alternative before approving a branded medication like ALVESCO.
  • Price Negotiations: Branded drug manufacturers engage in price negotiations with payers, but the leverage for older, off-patent drugs with generic competition is significantly diminished.
  • International Pricing Variations: Pricing and reimbursement policies vary widely by country, impacting global revenue. Countries with stronger price controls or national health systems often see lower average prices for pharmaceuticals.

The regulatory environment for generics is designed to promote competition and reduce healthcare costs. This fundamentally impacts the revenue potential of branded drugs like ALVESCO once their patents expire.

What are the Future Market Prospects and Strategic Considerations for ALVESCO?

The future market prospects for branded ALVESCO are characterized by continued competition from generics and a focus on niche segments or specific patient populations where its profile may still offer advantages.

• Diminishing Branded Sales: The trend of declining branded sales due to generic competition is expected to continue. Branded ALVESCO will likely transition from a primary treatment option to a secondary or alternative choice for specific circumstances.
• Focus on Loyalty and Niche Markets: Manufacturers may focus on maintaining relationships with physicians and patients who prefer the branded product, potentially through patient assistance programs or loyalty initiatives.
• Potential for Lifecycle Management: While less common for older, single-agent drugs with generic alternatives, manufacturers could theoretically explore new formulations, delivery devices, or combination therapies to extend the product's life. However, the investment required for such development is often not justified for drugs facing intense generic pressure.
• Impact of Evolving Asthma Treatment Guidelines: Changes in clinical guidelines for asthma management, which increasingly favor combination therapies (ICS/LABA) or biologics for severe asthma, could further reduce the market for single-agent ICSs like ALVESCO.
• Generic Market Dynamics: The ongoing development of new generic ciclesonide products and potential competition from other generic ICSs will further shape the market.

Strategic considerations for any entity involved with ALVESCO would include managing the decline of branded sales, optimizing costs associated with maintaining the brand, and potentially exploring opportunities within the generic ciclesonide market itself.

Key Takeaways

• ALVESCO's market is the global asthma inhalers segment, valued at approximately $20 billion in 2023 and projected to reach $29.5 billion by 2030 at a 5.5% CAGR.
• The primary patent expiry for ciclesonide in major markets, around 2017-2018 in the US, has enabled the introduction of generic alternatives.
• Branded ALVESCO revenue has experienced a significant decline post-patent expiry due to price erosion and market share loss to lower-cost generics.
• Key competitors include other ciclesonide formulations and widely prescribed ICSs like fluticasone propionate and budesonide, as well as combination therapies (ICS/LABA).
• Regulatory approvals are established, but generic drug pathways facilitate market entry for competitors. Reimbursement policies favor generics, impacting branded ALVESCO's formulary status and pricing.
• Future market prospects for branded ALVESCO are characterized by continued generic competition and a shift towards niche markets or physician/patient loyalty.

Frequently Asked Questions

What is the primary indication for ALVESCO?

ALVESCO is indicated for the maintenance treatment of asthma in patients aged 12 years and older.

When did the main patents for ciclesonide expire in the United States?

The main patents for ciclesonide expired in the United States around 2017-2018.

How does the introduction of generic ciclesonide affect the sales of branded ALVESCO?

The introduction of generic ciclesonide leads to significant price erosion and a substantial decline in sales and market share for branded ALVESCO.

Are there any currently approved biological treatments for asthma that directly compete with ALVESCO?

While biologics treat severe asthma and do not directly compete with single-agent ICSs like ALVESCO for mild-to-moderate asthma, they represent a significant therapeutic advancement in the broader asthma treatment landscape, potentially impacting the overall market for traditional inhalers over time.

What is the typical market share loss experienced by branded drugs after significant generic entry in the inhaler market?

Branded drugs in the inhaler market, like other pharmaceutical classes, can experience market share loss of 70-90% or more within a few years of significant generic entry, accompanied by a commensurate reduction in revenue.